Monday 12 December 2016

NCCN Guidelines® Recommend SIR-Spheres® Y-90 Resin Microspheres for the Treatment of Metastatic Colorectal Cancer
Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases.
Read more



Recent News (last 12 months)


Monday 21 November 2016

ELPA Calls on Patients with Primary Liver Cancer (HCC) to Share their Experiences in First Global Survey
ELPA has recently joined a special partnership with similar organisations across North America, Asia and Europe to ask hundreds of men and women with primary liver cancer (HCC) to share their experiences by responding to the first-ever international survey of people living with HCC.
Read more

Tuesday 11 October 2016

New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Sirtex Medical Limited (ASX:SRX) announced today that the European Society of Medical Oncology (ESMO) has indicated the use of SIRT using yttrium-90 (Y-90) microspheres as an option for the treatment of intrahepatic cholangiocarcinoma (iCCA), a form of primary liver cancer that starts in the bile duct, the branching network of thin tubes that deliver fat-digesting bile from the liver to the small intestine.
Read more


Download PDF Download PDF

Languages:

Thursday 06 October 2016

Liver Cancer Researchers from AP-HP and Singapore Collaborate on a Prospective Meta-Analysis of Two Studies of Y-90 resin microspheres versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma (HCC)
Cancer researchers from Assistance Publique – Hôpitaux de Paris (AP-HP) and The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore (NCCS) and Singapore Clinical Research Institute (SCRI) announced that they will collaborate on a prospective meta-analysis that will combine the impending results of two large, randomized controlled studies of Y-90 resin microspheres versus sorafenib. The two studies, which have completed patient recruitment, enrolled approximately 800 patients with advanced primary liver cancer (hepatocellular carcinoma or HCC).
Read more


Download PDF Download PDF

Languages:

Friday 09 September 2016

SIRT Users’ Network announces European expansion
The success of the SIRT Users’ Network, called SUN, in its first 2 years has created a strong desire for other countries to join. It has been announced today that SUN will expand to include health professionals from the United Kingdom, Belgium, Spain and Italy.
Read more


Download PDF Download PDF

Languages:

Friday 01 July 2016

Patients with Colorectal Cancer Liver Metastases Had Significantly Greater Depth of Tumour Response to SIR-Spheres® Y-90 resin microspheres, New SIRFLOX Analysis Shows
New data presented by Prof. Dr. Volker Heinemann in an oral abstract session at the European Society of Medical Oncology’s 18th World Congress on Gastrointestinal Cancer suggest that patients with liver-dominant mCRC treated first-line with the combination of mFOLFOX6 and SIR-Spheres Y-90 resin microspheres in the recently published SIRFLOX study experienced a much more profound response to treatment in the liver than those who received chemotherapy alone.
Read more


Download PDF Download PDF

Languages:

Monday 06 June 2016

SIRveNIB, a Major Primary Liver Cancer Study in the Asia-Pacific Region, Completes Enrolment
The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC), National Cancer Centre Singapore, Singapore Clinical Research Institute (SCRI) and Sirtex Medical Limited announced that the AHCC protocol 06 SIRveNIB randomised controlled study of SIR-Spheres Y-90 resin microspheres versus sorafenib in the treatment of unresectable primary liver cancer (hepatocellular carcinoma or HCC) has completed its target enrolment of at least 360 patients.
Read more


Download PDF Download PDF

Languages:

Thursday 12 May 2016

Leading South African Health Insurer Approves Reimbursement of SIR-Spheres® Y-90 resin microspheres
Discovery Health, the leading South African private health insurer, has agreed to reimburse SIR-Spheres Y-90 resin microspheres for the treatment of all forms of inoperable liver tumours.
Read more

Thursday 31 March 2016

SIR-Spheres® Y-90 resin microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says
Sirtex (ASX:SRX) announced today that the UK National Institute for Health and Care Excellence (NICE) has issued a new Medtech Innovation Briefing (MIB) stating that NHS doctors and commissioners may consider SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer (hepatocellular carcinoma or HCC).
Read more


Download PDF Download PDF

Languages:

Wednesday 16 March 2016

Netherlands Healthcare Institute Approves Reimbursement of Selective Internal Radiation Therapy (SIRT)
The Netherlands Healthcare Institute, Zorginstituut Nederland (ZIN), has agreed to reimburse Selective Internal Radiation Therapy (SIRT) for patients with colorectal liver metastases who have failed on or are intolerant to prior chemotherapy.
Read more


Download PDF Download PDF

Languages:

Monday 07 March 2016

Major Liver Cancer Study Completes Palliative Cohort Enrolment
Palliative Group of SORAMIC Study on Treatment of Locally Advanced Primary Liver Cancer with SIR-Spheres® Y-90 resin microspheres followed by Sorafenib Reaches 420-patient Enrolment Target
Read more


Download PDF Download PDF

Languages:

Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×